These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 26972499)

  • 1. Words of Wisdom. Re: Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.
    Mathieu R; Shariat SF
    Eur Urol; 2016 Apr; 69(4):755-6. PubMed ID: 26972499
    [No Abstract]   [Full Text] [Related]  

  • 2. Words of Wisdom. Re: Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.
    Murphy DG; Zargar H
    Eur Urol; 2016 Mar; 69(3):540. PubMed ID: 26867727
    [No Abstract]   [Full Text] [Related]  

  • 3. Re: Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.
    Taneja SS
    J Urol; 2016 Jan; 195(1):94. PubMed ID: 26699961
    [No Abstract]   [Full Text] [Related]  

  • 4. Chemohormonal Therapy in Hormone-Sensitive Prostate Cancer.
    Garcia JA; Sweeney C;
    N Engl J Med; 2016 Jan; 374(3):287. PubMed ID: 26789883
    [No Abstract]   [Full Text] [Related]  

  • 5. Chemohormonal Therapy in Hormone-Sensitive Prostate Cancer.
    Ciccarese C; Santoni M; Massari F
    N Engl J Med; 2016 Jan; 374(3):286. PubMed ID: 26789884
    [No Abstract]   [Full Text] [Related]  

  • 6. Words of Wisdom: Re: Chemohormonal Therapy in Metastatic Hormone-sensitive Prostate Cancer.
    de Reijke T
    Eur Urol; 2016 Jan; 69(1):178. PubMed ID: 27099882
    [No Abstract]   [Full Text] [Related]  

  • 7. Docetaxel for hormone-sensitive metastatic prostate cancer.
    Baker H
    Lancet Oncol; 2015 Sep; 16(9):e432. PubMed ID: 26278160
    [No Abstract]   [Full Text] [Related]  

  • 8. Adding chemotherapy to hormonal therapy prolongs survival in metastatic prostate cancer, study finds.
    Mayor S
    BMJ; 2015 Aug; 351():h4253. PubMed ID: 26251343
    [No Abstract]   [Full Text] [Related]  

  • 9. 'Charting a new course for prostate cancer' - currying favor for docetaxel in hormone-sensitive metastatic prostate cancer.
    Voskoboynik M; Staffurth J; Malik Z; Sweeney C; Chowdhury S
    Expert Rev Anticancer Ther; 2014 Nov; 14(11):1253-6. PubMed ID: 25353342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of early chemotherapy for hormone-sensitive prostate cancer: time for CHAARTED.
    Aragon-Ching JB
    Asian J Androl; 2016; 18(3):444-5. PubMed ID: 26510505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In hormone-naive metastatic prostate cancer, should all patients now receive docetaxel? No, not yet.
    Armstrong AJ
    Oncology (Williston Park); 2014 Oct; 28(10):881, 883. PubMed ID: 25323615
    [No Abstract]   [Full Text] [Related]  

  • 12. A one-two punch against prostate cancer.
    Johns Hopkins Med Lett Health After 50; 2014 Mar; 26(1):8. PubMed ID: 24937853
    [No Abstract]   [Full Text] [Related]  

  • 13. Prostate cancer: Docetaxel plus ADT significantly improves patient outcomes.
    Sidaway P
    Nat Rev Clin Oncol; 2015 Oct; 12(10):563. PubMed ID: 26305034
    [No Abstract]   [Full Text] [Related]  

  • 14. In hormone-naive metastatic prostate cancer, should all patients now receive docetaxel? Yes; we must beware of drawing conclusions from a subset analysis.
    Suzman DL; Antonarakis ES
    Oncology (Williston Park); 2014 Oct; 28(10):880, 882. PubMed ID: 25323614
    [No Abstract]   [Full Text] [Related]  

  • 15. Abiraterone and increased survival in metastatic prostate cancer.
    Sonpavde G
    N Engl J Med; 2011 Aug; 365(8):766-7; author reply 767-8. PubMed ID: 21864181
    [No Abstract]   [Full Text] [Related]  

  • 16. Chemohormonal therapy for metastatic hormone-sensitive prostate cancer: An Asian perspective.
    Teoh JY; Ng CF; Poon DM
    Asia Pac J Clin Oncol; 2018 Nov; 14 Suppl 5():5-8. PubMed ID: 30489034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in advanced prostate cancer - the continuing journey.
    Payne H; Davda R; Jones R; Crabb S; Troup J; Hughes S
    BJU Int; 2016 Jul; 118(1):17-9. PubMed ID: 26456636
    [No Abstract]   [Full Text] [Related]  

  • 18. [Docetaxel for metastatic prostate cancer: early is better].
    Gietema JA; Oosting SF
    Ned Tijdschr Geneeskd; 2016; 160():D215. PubMed ID: 27405569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CHAARTED/GETUG 12--docetaxel in non-castrate prostate cancers.
    Teo MY; Scher HI
    Nat Rev Clin Oncol; 2015 Dec; 12(12):687-8. PubMed ID: 26552950
    [No Abstract]   [Full Text] [Related]  

  • 20. Mapping the course after CHAARTED.
    Higano CS
    Nat Rev Urol; 2015 Dec; 12(12):656-8. PubMed ID: 26526753
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.